Table 3.
Monoclonal antibodies against PA30
| Antibody | Origin | Binding epitope | Mechanism of action | Efficacy animal model |
|---|---|---|---|---|
| Abthrax™ (GlaxoSmithKline) | Human | IV | Receptor binding inhibition | Rat, rabbit, and monkey |
| AVP-21D9 | Human | III | Blocks PA heptamer formation | Rat and rabbit |
| ETI-204 (Anthim™; Elusys Therapeutics, Inc., Pine Brook, NJ, USA) | Humanized | IV | Receptor binding inhibition | Rabbit |
| MDX 1303 (Valortim; PharmAthene, Inc., Annapolis, MD, USA) | Human | III | Disrupts preformed PA heptamers | Rabbit and monkey |
| IQNPA | Human | IV | Receptor binding inhibition | Mouse |
| W1 | Chimpanzee | IV | Receptor binding inhibition | Rat and mouse |
Abbreviation: PA, protective antigen.